about
Peto's paradox and the hallmarks of cancer: constructing an evolutionary framework for understanding the incidence of cancerCollaboration for rare disease drug discovery researchResearch progress of neuroblastoma related gene variations.Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cellsTargeting angiogenesis for controlling neuroblastoma.ALK-immunoreactive neoplasms.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.Apoptotic cell death in neuroblastoma.Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.Report of neuroblastoma in a set of monozygotic monochorionic twins.Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.Cell death-based treatment of neuroblastoma.
P2860
Q26849582-09F44F93-8214-48D3-A048-DC1448847F2AQ28650560-EA665A33-0B66-4BB8-B545-2EB9E0D83C69Q33566987-D88C70C8-514C-4777-B850-796967DA7533Q34101007-8B91E1F1-C8F4-4C54-8F1B-98416B214957Q35184831-0BF93980-0917-4D2B-99FB-71629EFE8FECQ36092957-2C6987DB-09B9-4B19-9D64-2C97B65252B6Q36145016-B05779F0-0FD0-4A5D-B91D-A1B629C34767Q37405597-53A0794D-5EDD-45F3-B5C7-F3117AB7E1FDQ37679253-BE984BDA-0D3F-4030-A960-3442359E66D6Q38042570-0F2B238D-9965-49C0-BB7D-C29192E33139Q38101044-0A9EA480-EF9E-4B35-BA68-E0523C2E9E78Q38980249-5C110C84-E27A-4E09-90E4-EC846B9BFB97Q39051444-EB43B793-1261-4234-AC5A-AADB0E8E3003Q40999620-7A10F425-42CF-43F4-9561-A3DA076D6336Q41879369-334FE140-923D-40E1-B59F-E10584AB55F0Q44636777-CC5D476A-7FB8-42F5-BCB3-77CEC8C554EDQ47442252-000DEAB0-0BF0-42DA-B062-F869F874A57FQ47839039-DF1E127F-870C-46C5-BE06-959452C115C1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic mutations of ALK in neuroblastoma.
@en
Oncogenic mutations of ALK in neuroblastoma.
@nl
type
label
Oncogenic mutations of ALK in neuroblastoma.
@en
Oncogenic mutations of ALK in neuroblastoma.
@nl
prefLabel
Oncogenic mutations of ALK in neuroblastoma.
@en
Oncogenic mutations of ALK in neuroblastoma.
@nl
P2093
P2860
P1433
P1476
Oncogenic mutations of ALK in neuroblastoma.
@en
P2093
Junko Takita
Masashi Sanada
Seishi Ogawa
Yasuhide Hayashi
P2860
P304
P356
10.1111/J.1349-7006.2010.01825.X
P577
2011-02-01T00:00:00Z